Results 61 to 70 of about 30,378 (204)

Effect of non-pharmacological interventions on chemotherapy induced delayed nausea and vomiting for tumors: A systematic review and Bayesian network meta-analysis

Complementary Therapies in Medicine
Objective: To evaluate the efficacy of non-pharmacological interventions in improving chemotherapy induced delayed nausea and vomiting symptoms using a network meta-analysis. Methods: Four Chinese databases (CNKI, Wanfang Data Knowledge Service Platform,
Yongni Wang, Fang Wang, Feifei Hu, Fang Long   +3 more
doaj   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study analyzes the current landscape of personalized cancer vaccine clinical trials, highlighting trends in vaccine platforms, trial phases, and geographic distribution. Peptide and dendritic cell vaccines dominate early‐stage research, with promising immune responses observed in melanoma, glioblastoma, and urothelial cancer trials.
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Phenotype, Management, and Outcomes in Paediatric Acute Pancreatitis: A Real‐Life Cross‐Sectional Study

Acta Paediatrica, EarlyView.
ABSTRACT Aim Limited Canadian data on paediatric acute pancreatitis exist. A meta‐analysis of 48 studies reported equal prevalence of acute pancreatitis among various aetiologies, with rates of severe acute pancreatitis at 13.7% in North America.
Catherine Korman, Doha Elhaoua, Sarah Blain, Thomas Li, Mariam Mohamed, Alessandro David, Colette Deslandres, Ugur Halac, Martha Dirks, Kelly Grzywacz, Michel Lallier, Fernando Alvarez, Prévost Jantchou   +12 more
wiley   +1 more source

The Effectiveness of P6 and Auricular Acupressure as a Complimentary Therapy in Chemotherapy-Induced Nausea and Vomiting Among Patients With Cancer: Systematic Review

Integrative Cancer Therapies
Background: Chemotherapy-induced nausea and vomiting (CINV) is one of the most prevalent and distressing side effects of chemotherapy among patients with cancer worldwide.
Bushra Alhusamiah MSN, PhD, Jumana Almomani MSN, PhD, Ahmad Al Omari MSN, PhD, Ala’a Abu attallah MSN, PhD, Afaf Yousef MSN, PhD, Jafar Alasad Alshraideh PhD, Ruqayya S. Zeilani PhD   +6 more
doaj   +1 more source

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA‐VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard‐dose cytarabine (‘7 + 3’) despite complete response (CR) rates of 50%–70%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA‐VEN) for intensive ...
Benjamin J. Lee, Shawn P. Griffin, Jean Doh, Anthony Quach, Yujiao Sun, Piyatida Chumnumsiriwath, Stefan O. Ciurea, Jorge Ramos‐Perez, Polina Bellman, Deepa Jeyakumar, Piyanuch Kongtim, Kiran Naqvi   +11 more
wiley   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source

Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron

Cancer Management and Research, 2009
Emilio Bajetta, Sara Pusceddu, Valentina Guadalupi, Monika Ducceschi, Luigi CelioMedical Oncology Unit 2, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, ItalyAbstract: Prevention of nausea and vomiting is the main goal of ...
Emilio Bajetta, Sara Pusceddu, Valentina Guadalupi, et al   +3 more
doaj  

Chemotherapy‐induced alopecia: an exploratory questionnaire‐based study from Israel comparing knowledge, attitudes, and management practices among dermatologists and oncologists

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives: Chemotherapy‐induced alopecia, encompassing both acute reversible alopecia and its persistent form, significantly impacts patients' quality of life but remains inadequately addressed. This study aimed to compare dermatologists' and oncologists' knowledge, attitudes, and practices regarding chemotherapy‐induced ...
Anna Lyakhovitsky, Oz Segal, Ester Vizan, Arad Dotan, Riad Kassem, Keren Lyakhovitsky, Avner Shemer, Baruch Kaplan, Eran Galili, Aviv Barzilai   +9 more
wiley   +1 more source

CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV): EFFICACY OF DIFFERENT ANTIEMETIC REGIMENS ACROSS EMETOGENIC RISK LEVELS

Journal of Gandhara Medical and Dental Sciences
OBJECTIVES This audit aimed to determine the efficacy of different antiemetic regimens across emetogenic risk levels in managing chemotherapy-induced vomiting and nausea.
Muhammad Umer Khayyam Azam, Bushra Haider, Nadia Qazi   +2 more
doaj   +1 more source